Key result
PAR-1 deficiency protects mice against diabetic nephropathy, reducing mesangial expansion, proteinuria, and tubular atrophy.
Why the study?
The net effect of protease-activated receptor-1 (PAR-1) activation on diabetic nephropathy progression was unclear due to its dual roles in limiting and promoting kidney injury.
Does PAR-1 deficiency protect against streptozotocin-induced diabetic nephropathy in mice?
Does PAR-1 deficiency protect against streptozotocin-induced diabetic nephropathy in mice?
p-value: p=<0.05
PAR-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice by reducing mesangial proliferation and extracellular matrix production, suggesting PAR-1 as a potential therapeutic target.
Hypothesis-generating for PAR-1 inhibition in diabetic nephropathy; human trials needed before clinical adoption.
Endogenously administered activated protein C ameliorates diabetic nephropathy (DN) in a protease-activated receptor-1 (PAR-1)-dependent manner, suggesting that PAR-1 activation limits the progression of DN. Activation of PAR-1 in fibroblast-like cells, however, induces proliferation and extracellular matrix production, thereby driving fibrotic disease. Considering the key role of mesangial proliferation and extracellular matrix production during DN, PAR-1 may in fact potentiate diabetes-induced kidney injury. To determine the net effect of PAR-1 in DN, streptozotocin-induced DN was studied in wild type and PAR-1 deficient mice. Subsequent mechanistic insight was obtained by assessing profibrotic responses of mesangial and tubular epithelial cells in vitro, following PAR-1 stimulation and inhibition. Despite having similar glucose levels, PAR-1 deficient mice developed less kidney damage after induction of diabetes, as evidenced by diminished proteinuria, plasma cystatin C levels, expansion of the mesangial area, and tubular atrophy. In vitro, PAR-1 signaling in mesangial cells led to increased proliferation and expression of matrix proteins fibronectin and collagen IV. Conversely, a reduction in both proliferation and fibronectin deposition was observed in diabetic PAR-1 deficient mice. Overall, we show that PAR-1 plays an important role in the development of DN and PAR-1 might therefore be an attractive therapeutic target to pursue in DN.
No takes yet. Share an insight, caveat, or question.
Waasdorp et al. (2016) studied Diabetic nephropathy (n=31). PAR-1 deficiency vs. Wild type mice was evaluated on Development of diabetic nephropathy (proteinuria, plasma cystatin C, mesangial expansion) (p=<0.05). PAR-1 deficiency protected mice against streptozotocin-induced diabetic nephropathy, significantly reducing mesangial expansion, proteinuria, and tubular atrophy compared to wild type mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: